TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03902301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus group
Description: Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary group
Description: Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
Study: NCT02596633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-support Acceptance and Commitment Therapy (ACT)
Description: Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
Study: NCT01989676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
Study: NCT00354562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-751
Description: 200mg ABT-751 daily for 14 days every 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 14 days every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Standard Docetaxel every 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Standard Docetaxel every 21 days
Study: NCT01275716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications
Description: Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
Study: NCT04688372

Intervention type: OTHER
Intervention: Surge Index
Description: See study description above
Study: NCT01114581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucinex
Description: Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given as 2 tablets
Study: NCT00537017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 5 mg BID capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
Study: NCT03436953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-8998
Description: T-type calcium channel blocker
Study: NCT01197664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given PO
Study: NCT01722123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
Study: NCT00066638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01685866

Intervention type: DEVICE
Group type: OTHER
Intervention: Vein-Viewer Vision
Description: A medical device called Vein-Viewer Vision
Study: NCT01814384

Intervention type: DEVICE
Group type: OTHER
Intervention: prosthesis GMK ® without the ancillary MyKnee ® LBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Matched patient cutting blocks MyKnee ® LBS
Study: NCT03484377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
Study: NCT01805440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uridine
Description: Uridine is the active treatment in this clinical trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Study: NCT00993902

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intrauterine insemination (single)
Description: Single IUI after 36-38 hours of HCG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double intrauterine insemination
Description: Double insemination after 18 and 40 hours of HCG administration.
Study: NCT02095223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback
Description: Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Exercise
Description: All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise
Description: All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
Study: NCT00509041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 50 mg PO bid
Study: NCT01907997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic intravenous lidocaine infusion
Description: In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline infusion
Description: In group C, the patients receive same volume of normal saline
Study: NCT03484637

Intervention type: OTHER
Intervention: Lifestyle-medicine intervention
Study: NCT03926871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic Training
Description: The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic Training
Description: The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
Study: NCT01858376

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Capros dietary supplement
Description: Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
Study: NCT01391754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare
Description: Behavioral home based family preservation. Weekly visits X six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare
Description: Behavioral home based family preservation. Weekly visits X six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo coached quality control
Description: Live observation of practice with expert coaching, feedback and fidelity monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo coached quality control
Description: Live observation of practice with expert coaching, feedback and fidelity monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services As Usual
Description: Home based services not using the SafeCare model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services As Usual
Description: Home based services not using the SafeCare model

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncoached
Description: No in vivo coached quality control or fidelity monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncoached
Description: No in vivo coached quality control or fidelity monitoring
Study: NCT02186873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 2mg/kg of intravenous infusions of golimumab .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 2mg/kg of intravenous infusions of golimumab .
Study: NCT04875962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
Study: NCT01593410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg oral lenalidomide once daily on Days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
Study: NCT04200560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Handgrip Exercise
Description: 60 minute rhythmic handgrip exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Handgrip Exercise
Description: 60 minute rhythmic handgrip exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic Exercise Training
Description: Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
Study: NCT00806975

Intervention type: DEVICE
Group type: OTHER
Intervention: KwikPen® and FlexPen®
Description: The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
Study: NCT03587948

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes mellitus
Description: Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
Study: NCT01007149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
Study: NCT05544409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAKv1
Description: 1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
Study: NCT01007149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in vials with solution for subcutaneous injection.
Study: NCT00867685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Single dose of 40 mg AZD2624 liquid suspension, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Single dose of 40 mg AZD 2624 (2x20mg tablets), PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
Study: NCT02841189

Intervention type: DEVICE
Group type: OTHER
Intervention: King Vision video Laryngoscope
Description: The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
Study: NCT00810108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (Kaletra®) tablets
Description: The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (Kaletra®) tablets
Description: The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
Study: NCT01286727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB3
Description: intravenous drug
Study: NCT02439294

Intervention type: OTHER
Group type: OTHER
Intervention: Without Obstructive Sleep Apnea (syndrome)

Intervention type: OTHER
Group type: OTHER
Intervention: Mild or moderate Obstructive Sleep Apnea (syndrome)

Intervention type: OTHER
Group type: OTHER
Intervention: Severe Obstructive Sleep Apnea (syndrome)

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Study: NCT04355507

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest computed tomography (CT)
Description: Chest computed tomography (CT) examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse-transcription polymerase chain reaction (RT-PCR)
Description: Identification of viral RNA by reverse-transcription polymerase chain reaction
Study: NCT00068328

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study: NCT02753933

Intervention type: OTHER
Intervention: MRI scan
Description: MRI head scan to be performed as the first Secondary Care contact.

Intervention type: OTHER
Intervention: Neurology Appointment
Description: Outpatient appointment with Neurologist as the first Secondary Care contact
Study: NCT04171154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation
Description: writing task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance
Description: listening
Study: NCT02040194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for intratympanic injection
Study: NCT04252573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chimney Endovascular Aortic Sealing (ChEVAS) System
Description: The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
Study: NCT01226316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
Study: NCT03436953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT01065389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training
Description: Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured Nonprogressive resistance exercise
Description: Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.